Intraoperative effects of dexmedetomidine infusion in adult living donors undergoing hepatic resections for liver transplantation: A randomized control trial.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR201909557694667

Enrollment

Registered

2019-09-20

Start date

2015-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

dexmedetomidine group dex group

control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All donors fulfilled the eligibility criteria for donation including a within normal liver histology and a volumetric study of the whole liver and the right lobe.Age 18-45 years old, ASA I, normal liver functions, coagulation profiles and normal renal functions.

Exclusion criteria

Exclusion criteria: inability to give written consent, hemoglobin level < 10 g/dl. Any contraindication for donation.

Design outcomes

Primary

Measure	Time frame
we primary investigated the ability of intraoperative infusion of dex in adult living donors undergoing hepatic resections for liver transplantation in the protection of the hepatic parenchyma assessed by laboratory data , including ALT, AST, bilirubin, INR, and lactate (reflecting the degree of hepatocellular injury, elimination and synthetic dysfunctions) and serum ICAM-1 level measurement (reflecting the magnitude of the endothelial cell damages and the severity of inflammatory reactions .	—

Measure

Time frame

we primary investigated the ability of intraoperative infusion of dex in adult living donors undergoing hepatic resections for liver transplantation in the protection of the hepatic parenchyma assessed by laboratory data , including ALT, AST, bilirubin, INR, and lactate (reflecting the degree of hepatocellular injury, elimination and synthetic dysfunctions) and serum ICAM-1 level measurement (reflecting the magnitude of the endothelial cell damages and the severity of inflammatory reactions .

—

Secondary

Measure	Time frame
secondary we evaluated the effects of Dex infusion on the general anaesthetic requirements.	—

Countries

Egypt

Contacts

Public Contacthesham maged

heshammaged2005@yahoo.com0123548537

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026